Drugs / EP547
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04510090 | Sep 2020 → Jul 2021 | cholestasis, kidney failure | Escient Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05525520 | Oct 2022 → Jul 2024 | — | Escient Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EP547 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04510090 ↗ |